CA-125 monitoring in ovarian cancer: Patient survey responses to the results of the mrc/eortc CA-125 surveillance trial

Oncology

Volumn 78, Issue 1, 2010, Pages 1-2

  Markman, Maurie ^a   Petersen, Judith ^b   Belland, Angela ^b   Burg, Kenda ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NexCura Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN;

CANCER CHEMOTHERAPY; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; EDITORIAL; HEALTH SURVEY; HUMAN; OVARY CANCER; PATIENT INFORMATION; PATIENT MONITORING; PRIORITY JOURNAL; QUESTIONNAIRE;

CA-125 ANTIGEN; FEMALE; HEALTH CARE SURVEYS; HUMANS; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR MARKERS, BIOLOGICAL;

EID: 77649317424     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000292352     Document Type: Editorial

References (9)

1. Covens A, Carey M, Bryson P, Verma S, Fung Kee FM, Johnston M: Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. Gynecol Oncol 2002; 85: 71-80.
2. Meyer T, Rustin GJ: Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer 2000; 82: 1535-1538.
3. Hogdall E: Cancer antigen 125 and prognosis. Curr Opin Obstet Gynecol 2008; 20: 4-8.
4. Markman M: Follow-up of the asymptomatic patient with ovarian cancer. Gynecol Oncol 1994; 55:S134-S137.
5. Rustin GJ, van der Burg E, on behalf of MRC and EORTC Collaborators: A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OVO5/ EORTC 55955 trials). J Clin Oncol 2009; 27(18S):793s, abstract 1.
6. Markman M, Markman MR, Belland A, Petersen J: Profile of ovarian cancer patients seeking information from a web-based decision support program. J Womens Health (Larchmt) 2006; 15: 312-318.
7. Markman M, Markman M, Petersen J, Belland A: Clinical features of American versus non-American gynecologic cancer patients requesting information from a proprietary web-based decision-support program. J Cancer Res Clin Oncol 2006; 132: 439-443.
8. Meza JP, Webster DS: Patient preferences for laboratory test results notification. Am J Manag Care 2000; 6: 1297-1300.
9. Baldwin DM, Quintela J, Duclos C, Staton EW, Pace WD: Patient preferences for notification of normal laboratory test results: a report from the ASIPS Collaborative. BMC Fam Pract 2005; 6: 11.